Development of a live biotherapeutic throat spray with lactobacilli targeting respiratory viral infections
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Respiratory viruses such as influenza viruses, respiratory syncytial virus (RSV), and coronaviruses initiate infection at the mucosal surfaces of the upper respiratory tract (URT), where the resident respiratory microbiome has an important gatekeeper function. In contrast to gut‐targeting administration of beneficial bacteria against respiratory viral disease, topical URT administration of probiotics is currently underexplored, especially for the prevention and/or treatment of viral infections. Here, we report the formulation of a throat spray with live lactobacilli exhibiting several in vitro mechanisms of action against respiratory viral infections, including induction of interferon regulatory pathways and direct inhibition of respiratory viruses. Rational selection of Lactobacillaceae strains was based on previously documented beneficial properties, up‐scaling and industrial production characteristics, clinical safety parameters, and potential antiviral and immunostimulatory efficacy in the URT demonstrated in this study. Using a three‐step selection strategy, three strains were selected and further tested in vitro antiviral assays and in formulations: Lacticaseibacillus casei AMBR2 as a promising endogenous candidate URT probiotic with previously reported barrier‐enhancing and anti‐pathogenic properties and the two well‐studied model strains Lacticaseibacillus rhamnosus GG and Lactiplantibacillus plantarum WCFS1 that display immunomodulatory capacities. The three strains and their combination significantly reduced the cytopathogenic effects of RSV, influenza A/H1N1 and B viruses, and HCoV‐229E coronavirus in co‐culture models with bacteria, virus, and host cells. Subsequently, these strains were formulated in a throat spray and human monocytes were employed to confirm the formulation process did not reduce the interferon regulatory pathway‐inducing capacity. Administration of the throat spray in healthy volunteers revealed that the lactobacilli were capable of temporary colonization of the throat in a metabolically active form. Thus, the developed spray with live lactobacilli will be further explored in the clinic as a potential broad‐acting live biotherapeutic strategy against respiratory viral diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984 · cited 1×
“Severe disease caused by viruses is often accompanied by reduced type I and III interferon (IFN) production and/or overproduction of pro- inflammatory mediators (Berri et al., 2014; Blanco- Melo et al., 2020; Jérôme et al., 2020).”
BackgroundSwanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
The microbiota of the respiratory tract: gatekeeper to respiratory health
Man, W. H., de Steenhuijsen Piters, W. A. A., & Bogaert, D. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.14 · Cited by 1,384 · cited 2×
“The respiratory mucosal surfaces targeted by viruses also harbour a microbiome consisting of resident microorganisms which have important multifactorial gatekeeper functions, including direct inhibition of incoming pathogens, maintaining epithelial barrier function, and immune homeostasis (Man et al., 2017).”
BackgroundSelective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120 · cited 1×
“HCoV229E generally causes mild symptoms, but it has several features in common with SARS- CoV2, such as homologous epitopes of the spike protein, and is suitable for high- throughput screening due to biosafety level 2 (Mateus et al., 2020).”
BackgroundMicrobes, Metabolites, and the Gut-Lung Axis
Dang, A. T., & Marsland, B. J. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0160-6 · Cited by 1,028
Pretzer, G., Snel, J., Molenaar, D., Wiersma, A., Bron, P. A., Lambert, J., de Vos, W. M., van der Meer, R., Smits, M. A., & Kleerebezem, M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.17.6128-6136.2005 · Cited by 316
Self-citationIRF family proteins and type I interferon induction in dendritic cells
Tailor, P., Tamura, T., & Ozato, K. (2006) · Cell Research · doi:10.1038/sj.cr.7310018 · Cited by 186
DeMuri, G. P., Gern, J. E., Eickhoff, J. C., Lynch, S. V., & Wald, E. R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix941 · Cited by 136
Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli
Lebeer, S., Oerlemans, E. F. M., Claes, I., Henkens, T., Delanghe, L., Wuyts, S., Spacova, I., van den Broek, M. F. L., Tuyaerts, I., Wittouck, S., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100521 · Cited by 95 · cited 1×
“Of note, similar criteria have previously allowed us to develop a multi- strain probiotic formulation for topical skin application against acne (Lebeer et al., 2022).”
BackgroundSelf-citation
Cited by
Surface layer proteins in species of the family Lactobacillaceae
Palomino, M. M., Allievi, M. C., Gordillo, T. B., Bockor, S. S., Fina Martin, J., & Ruzal, S. M. (2023) · Microbial Biotechnology · doi:10.1111/1751-7915.14230 · Cited by 34
“Probiotics have proven to be a good strategy for the modulation of the human intestinal and vaginal microbiota, as well as to stimulate the systemic and mucosal immune response to prevent and treat infectious diseases (De Boeck et al., 2021; Håkansson et al., 2019; Spacova et al., 2023).”
BackgroundGizachew, S., Van Beeck, W., Spacova, I., Dekeukeleire, M., Alemu, A., Woldemedhin, W. M., Mariam, S. H., Lebeer, S., & Engidawork, E. (2023) · Fermentation · doi:10.3390/fermentation9030258 · Cited by 26
“This supports previous results on LAB that immunostimulatory activity is strain-specific [32] and highlights the need to select appropriate probiotic strains for each envisioned application.”
BackgroundMethodResultInfluentialSelf-citationGizachew, S., & Engidawork, E. (2024) · Genes · doi:10.3390/genes15111389 · Cited by 15
Metadata
- Authors
- Spacova, I., De Boeck, I., Cauwenberghs, E., Delanghe, L., Bron, P. A., Henkens, T., Simons, A., Gamgami, I., Persoons, L., Claes, I., van den Broek, M. F. L., Schols, D., Delputte, P., Coenen, S., Verhoeven, V., & Lebeer, S.
- Venue
- Microbial Biotechnology
- Publisher
- Wiley
- Published
- 2022-12-05
- Volume
- 16
- Issue
- 1
- Pages
- 99-115
- ISSN
- 1751-7915 (ISSN-L)
- OpenAlex
- W4310701645
- Cited by
- 36
- References
- 9
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of a live biotherapeutic throat spray with lactobacilli targeting respiratory viral infections. https://app.cochat.ai/papers/10.1111/1751-7915.14189
- The paper
- Spacova, I., De Boeck, I., Cauwenberghs, E., Delanghe, L., Bron, P. A., Henkens, T., Simons, A., Gamgami, I., Persoons, L., Claes, I., van den Broek, M. F. L., Schols, D., Delputte, P., Coenen, S., Verhoeven, V., & Lebeer, S. (2023). Development of a live biotherapeutic throat spray with lactobacilli targeting respiratory viral infections. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.14189
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.